GENinCode
Oxford
About GENinCode
GEN inCode specializes in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GEN inCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. Our products help inform patients of their health risk enabling them to make behavioral or ‘lifestyle’ changes whilst providing doctors with greater genetic insight and clinical information to determine the most effective treatment pathway (precision medicine). GEN inCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our polygenic tests combine clinical-genetic algorithms with AI to provide an advanced patient risk assessment to predict disease onset.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2023)
- Ticker: lse:GENI
- Website: genincode.com
- Phone: +44 7800 903435
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/genincode-1518 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.